Letters to the Editor

Efficacy and safety of chimeric antigen receptor T-cell therapy for plasma cell leukemia

Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China; Blood Diseases Institute, Xuzhou Medical University, Xuzhou, China; Key Laboratory of Bone Marrow Stem Cells, Xuzhou Medical University, Xuzhou
Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou
Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China; Department of Cardiology, The Affiliated Sihong Hospital of Xuzhou Medical University, Xuzhou
Haematology Research Centre, Department of Immunology and Inflammation, Imperial College London, London
Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou
Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou
Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou
Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou
Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou
Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou
Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou
Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China; Blood Diseases Institute, Xuzhou Medical University, Xuzhou, China; Key Laboratory of Bone Marrow Stem Cells, Xuzhou Medical University, Xuzhou, China; Center for Sci-Tech Innovation and Public Service, The Affiliated Hospital of Xuzhou Medical University, Xuzhou
Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China; Blood Diseases Institute, Xuzhou Medical University, Xuzhou, China; Key Laboratory of Bone Marrow Stem Cells, Xuzhou Medical University, Xuzhou
Haematologica Early view Mar 19, 2026 https://doi.org/10.3324/haematol.2026.000001